randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy随机、安慰剂对照试验mipomersen严重高胆固醇血症患者接受最大限度容忍降脂治疗.pdfVIP

randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy随机、安慰剂对照试验mipomersen严重高胆固醇血症患者接受最大限度容忍降脂治疗.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy随机、安慰剂对照试验mipomersen严重高胆固醇血症患者接受最大限度容忍降脂治疗

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy 1 2 3 4 5 Mary P. McGowan *, Jean-Claude Tardif , Richard Ceska , Lesley J. Burgess , Handrean Soran , 6 7 8 Ioanna Gouni-Berthold , Gilbert Wagener , Scott Chasan-Taber ´ 1 Cardiometabolic Risk Reduction and Research Center of New England, Bedford, New Hampshire, United States of America, 2 Montreal Heart Institute, Universite de ´ Montreal, Montreal, Quebec, Canada, 3 Centre for Preventive Cardiology, General Teaching Hospital and First Medical Faculty of Charles University in Prague, Prague, Czech Republic, 4 Cardiology Unit, Stellenbosch University and Tygerberg Hospital, Parow, South Africa, 5 University Department of Medicine, Central Manchester Foundation Trust, Manchester, United Kingdom, 6 Center of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany, 7 Clinical Research, Genzyme Corporation, Almere Stad Area, The Netherlands, 8 Biostatistics, Genzyme Corporation, Cambridge, Massachusetts, United States of America Abstract Objectives: Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated. Methods and Resul

您可能关注的文档

文档评论(0)

xyz118 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档